Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Intermountain Healthcare, a Utah-based, nonprofit healthcare system, which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients. Intermountain Healthcare is leveraging Tempus’ solid tumor/normal genomic test, xT, to generate w...
Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to provide broader access to genomic testing to patients with advanced/metastatic non-small cell lung cancer (NSCLC). Leveraging Tempus tests, this collaboration is intended to help physicians understand th...
Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked a collection of its broad-panel genomic sequencing assays and predictive algorithm laboratory-developed tests. Alongside xT, its primary broad-panel, next-generation sequencing assay, already available on the market, additional Tempus CE marked tests are now...
Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes in Chicago from June 3-7, 2022. Tempus is presenting fourteen abstracts, including one oral presentation, two poster discussions, and eleven poster presentations. “The re...
Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its comprehensive genomic profiling offerings with xF+, a new non-invasive, liquid biopsy panel of 523 genes, focused on pathogenic mutations in cell-free DNA (cfDNA). The test will originally be available on a limited basis alongside xF, Temp...
Published in Circulation, the rECHOmmend study expands on AI-focused research to improve patient outcomes in cardiology A team of clinicians and scientists from Tempus and Geisinger have found that a new artificial intelligence model can accurately identify patients at increased risk of undiagnosed structural heart disease....
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Tempus N+, a program that aims to power precision medicine solutions through the use of real-world data for mental health. Tempus is collaborating with academic medical institutions around the country to create a sustainable and secure...
Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year agreement with the United States Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) designed to expand access to Tempus’ portfolio of next-generation sequencing offerings to support physicians in delivering personalized treatment approaches for their p...
Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which convenes in New Orleans from April 8th until April 13th, 2022. The presented research demonstrates how Tempus’ comprehensive genomic sequencing capabilities generate high-quali...
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide. With access to over 50 petabytes of de-identified multi...